Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan

Stock Information for Vanda Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Reports Positive Results from a Second Phase III Study of Tradipitant in Motion Sickness
Vanda Pharmaceuticals Reports First Quarter 2024 Financial Results
Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak
Vanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024
Shareholder Capital Delivers Letter to Independent Members of the Board of Vanda Pharmaceuticals
Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ® ANDA Litigation
Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pak
Vanda Pharmaceuticals' Fanapt® (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.